PHVS (Pharvaris NV) Common Stock : $7.22 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Common Stock?

Pharvaris NV's quarterly common stock declined from Mar. 2024 ($7.02 Mil) to Jun. 2024 ($6.98 Mil) but then increased from Jun. 2024 ($6.98 Mil) to Sep. 2024 ($7.22 Mil).

Pharvaris NV's annual common stock declined from Dec. 2021 ($4.50 Mil) to Dec. 2022 ($4.30 Mil) but then increased from Dec. 2022 ($4.30 Mil) to Dec. 2023 ($6.84 Mil).

Pharvaris NV Common Stock Historical Data

The historical data trend for Pharvaris NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Common Stock Chart

Pharvaris NV Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.15

0.29

4.50

4.30

6.84

Pharvaris NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial															5.25	6.84	7.02	6.98	7.22

Pharvaris NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Pharvaris NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

9EN:Germany

Address

Emmy Noetherweg 2, Leiden, NLD, 2333 BK

Website

https://www.pharvaris.com

Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.